Physician profile
Stuart W Moser
NPI 1275579443
$1,182.47
in general payments reported to CMS, 2019-2025
15 companies · $757 in 2025
The $757 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2021: $19.50 · 2022: $76.79 · 2023: $106 · 2024: $30.75 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.92 | 2025 | Lifevest |
| Bridgebio Pharma, INC. | $167.35 | 2025 | Attruby |
| Boston Scientific Corporation | $144.36 | 2025 | General - Therapies |
| Abbott Laboratories | $138.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $134.56 | 2019-2025 | |
| Abiomed | $133.21 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.68 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $51.98 | 2019-2024 | Camzyos |
| Pfizer INC. | $45.56 | 2022-2024 | |
| Philips North America LLC | $31.61 | 2025 | Extended Holter |
| Novo Nordisk INC | $25.33 | 2025 | Ozempic |
| Amgen INC. | $22.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.77 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $17.73 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $13.95 | 2023 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Moser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.